PBM Reforms May Open a New Era for Group Health Plan Sponsors

Why It Matters

Employers gain unprecedented transparency and bargaining power over drug‑cost structures, while PBMs confront stricter compliance and potential fiduciary exposure.

Key Takeaways

• CAA 2026 mandates 100% rebate pass‑through
• PBMs now ERISA covered service providers
• Audit rights granted to plan sponsors
• Reporting starts 2029 for calendar‑year plans
• DOL proposed rules lack full pass‑through

Pulse Analysis

The 2026 Consolidated Appropriations Act marks the most comprehensive federal effort to rein in pharmacy benefit managers, extending ERISA’s covered‑service‑provider rules to PBMs. By forcing full rebate pass‑through and detailed compensation reporting, the law aims to eliminate opaque spread pricing that has long inflated prescription costs for employers. This legislative shift aligns PBM oversight with that of investment advisors and record‑keepers, compelling sponsors to scrutinize fee structures and negotiate contracts on a more level playing field.

For plan sponsors, the immediate audit rights and quarterly rebate remittance requirements reshape contract negotiations. Employers can now demand transparent, drug‑by‑drug pricing data and verify that manufacturers’ rebates flow directly to the health plan, reducing the risk of hidden profit margins. The 2029 compliance deadline gives large groups time to adjust legacy contracts, but savvy employers are already revisiting renewal terms to embed audit clauses and enforce the new disclosure standards, thereby protecting fiduciaries from inadvertent breaches.

Regulatory guidance from the Department of Labor’s Employee Benefits Security Administration is expected to dovetail with the CAA, though its proposed rules stop short of mandating full rebate pass‑through. The convergence of statutory and regulatory requirements creates a dual compliance track that sponsors must monitor. As the DOL finalizes its rules, the industry anticipates clearer audit protocols and potential civil penalties for non‑compliance, reinforcing the trend toward greater transparency and cost control in the pharmacy benefits market.